Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Spinocerebellar Ataxia Pipeline Drugs Market Overview

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Its symptoms include poor coordination, unsteady walking, change in speech, and difficulty swallowing.

The Spinocerebellar Ataxia pipeline market research report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinocerebellar Ataxia and features dormant and discontinued projects.

Spinocerebellar Ataxia Pipeline Products Market Segmentation by Targets

The key targets in the Spinocerebellar Ataxia pipeline products market are Ataxin 3, Ataxin 1, Ataxin 2, Calcium Activated Neutral Protease, Excitatory Amino Acid Transporter 2, Huntingtin, Polyadenylate Binding Protein 2, Adenosine Receptor A2a, Ataxin 10, Calcium Activated Potassium Channel, and others.

Spinocerebellar Ataxia Pipeline Products Market Analysis by Targets

Spinocerebellar Ataxia Pipeline Products Market Analysis by Targets

For more target insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample

Spinocerebellar Ataxia Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Spinocerebellar Ataxia pipeline products market are Ataxin 3 Inhibitor, Ataxin 1 Inhibitor, Ataxin 2 Inhibitor, Calcium Activated Neutral Protease Inhibitor, Excitatory Amino Acid Transporter 2 Activator, Polyadenylate Binding Protein 2 (Poly(A) Binding Protein 2 or Nuclear PolyInhibitor, Adenosine Receptor A2a Agonist, Ataxin 10 Inhibitor, Calcium Activated Potassium Channel Activator, DNA Mismatch Repair Protein Msh3 Inhibitor, and others.

Spinocerebellar Ataxia Pipeline Products Market Analysis by Mechanisms of Action

Spinocerebellar Ataxia Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample

Spinocerebellar Ataxia Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Spinocerebellar Ataxia pipeline products market are oral, intravenous, intrathecal, intraarticular, parenteral, intrauterine, and nasal.

Spinocerebellar Ataxia Pipeline Products Market Analysis by Routes of Administration

Spinocerebellar Ataxia Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample

Spinocerebellar Ataxia Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Spinocerebellar Ataxia pipeline products market are small molecule, antisense oligonucleotide, cell therapy, gene therapy, oligonucleotide, antisense RNAi oligonucleotide, recombinant protein, and RNAi gene therapy.

Spinocerebellar Ataxia Pipeline Products Market Analysis by Molecule Types

Spinocerebellar Ataxia Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Spinocerebellar Ataxia pipeline products market are Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, Biogen Inc, BioXcel Corp, and Celavie Biosciences LLC.

Spinocerebellar Ataxia Pipeline Products Market Analysis by Players

Spinocerebellar Ataxia Pipeline Products Market Analysis by Players

To know more about the leading players in the Spinocerebellar Ataxia pipeline products market, download a free report sample

Spinocerebellar Ataxia Pipeline Products Market Report Overview

Key Targets Ataxin 3, Ataxin 1, Ataxin 2, Calcium Activated Neutral Protease, Excitatory Amino Acid Transporter 2, Huntingtin, Polyadenylate Binding Protein 2, Adenosine Receptor A2a, Ataxin 10, Calcium Activated Potassium Channel, and Others
Key Mechanisms of Action Ataxin 3 Inhibitor, Ataxin 1 Inhibitor, Ataxin 2 Inhibitor, Calcium Activated Neutral Protease Inhibitor, Excitatory Amino Acid Transporter 2 Activator, Polyadenylate Binding Protein 2 (Poly(A) Binding Protein 2 or Nuclear PolyInhibitor, Adenosine Receptor A2a Agonist, Ataxin 10 Inhibitor, Calcium Activated Potassium Channel Activator, DNA Mismatch Repair Protein Msh3 Inhibitor, and Others
Key Routes of Administration Oral, Intravenous, Intrathecal, Intraarticular, Parenteral, Intrauterine, and Nasal
Key Molecule Type Small Molecule, Antisense Oligonucleotide, Cell Therapy, Gene Therapy, Oligonucleotide, Antisense RNAi Oligonucleotide, Recombinant Protein, and RNAi Gene Therapy
Leading Players Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, Biogen Inc, BioXcel Corp, and Celavie Biosciences LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Anima Biotech Inc
Annji Pharmaceutical Co Ltd
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Blade Therapeutics Inc
Celavie Biosciences LLC
Corestem Inc
Dystrogen Therapeutics SA
Enzerna Biosciences LLC
Everfront Biotech Inc
Exicure Inc
Gene Therapy Research Institution Co Ltd
IntraBio Ltd
Ionis Pharmaceuticals Inc
Locanabio Inc
Novartis AG
PTC Therapeutics Inc
Q-State Biosciences Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics, Inc.
Shionogi & Co Ltd
Steminent Biotherapeutics Inc
Triplet Therapeutics Inc
Vico Therapeutics BV
Vybion Inc
Wave Life Sciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Spinocerebellar Ataxia (SCA) – Overview

Spinocerebellar Ataxia (SCA) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Spinocerebellar Ataxia (SCA) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Spinocerebellar Ataxia (SCA) – Companies Involved in Therapeutics Development

Spinocerebellar Ataxia (SCA) – Drug Profiles

Spinocerebellar Ataxia (SCA) – Dormant Projects

Spinocerebellar Ataxia (SCA) – Discontinued Products

Spinocerebellar Ataxia (SCA) – Product Development Milestones

Featured News & Press Releases

May 23, 2022: Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA)

Nov 08, 2021: Seelos Therapeutics announces FDA acceptance of investigational new drug application and grant of fast track designation for SLS-005 (IV Trehalose) for the treatment of Spinocerebellar Ataxia

Oct 07, 2021: Blade Therapeutics announces publication of preclinical evidence supporting neuroprotective effects of proprietary calpain inhibitor in a rare inherited neurodegenerative disease

Jun 29, 2021: US FDA grants VICO therapeutics orphan-drug designation for VO659, an investigational therapy for spinocerebellar ataxia

Apr 13, 2021: Biohaven announces presentations on troriluzole at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

Mar 29, 2021: SM Life Sciences submits IND for spinal cerebellar ataxia treatment

Feb 10, 2021: European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an investigational herapy for spinocerebellar ataxia

Dec 21, 2020: Seelos Therapeutics announces issuance of a patent for Trehalose (SLS-005) in Israel

Nov 11, 2020: Biohaven Pharmaceuticals inaugural partner Of National Ataxia Foundation’s drug development collaborative

Jan 23, 2020: Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for Spinocerebellar Ataxia (SCA)

Jan 22, 2020: Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry

Dec 04, 2019: Seelos Therapeutics receives notice of allowance for an additional US patent for Trehalose (SLS-005)

May 29, 2019: Cadent Therapeutics announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia

May 07, 2019: Biohaven advances late stage clinical program and novel targets from neuroinnovation platform

May 03, 2019: Biohaven announces presentation of Troriluzole in phase IIb/III trial at American Academy Of Neurology (AAN) 2019 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Anima Biotech Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Annji Pharmaceutical Co Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Biogen Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by BioXcel Corp, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Blade Therapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Celavie Biosciences LLC, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Corestem Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Dystrogen Therapeutics SA, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Enzerna Biosciences LLC, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Everfront Biotech Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Exicure Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Gene Therapy Research Institution Co Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by IntraBio Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Ionis Pharmaceuticals Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Locanabio Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Novartis AG, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by PTC Therapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Q-State Biosciences Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Sclnow Biotechnology Co Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Seelos Therapeutics, Inc., 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Shionogi & Co Ltd, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Steminent Biotherapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Triplet Therapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Vico Therapeutics BV, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Vybion Inc, 2022

Spinocerebellar Ataxia (SCA) – Pipeline by Wave Life Sciences Ltd, 2022

Spinocerebellar Ataxia (SCA) – Dormant Projects, 2022

Spinocerebellar Ataxia (SCA) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.